Katharine Peterson's Insider Trades & SAST Disclosures
Katharine Peterson's most recent trade in Acrivon Therapeutics Inc was a trade of 31,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Katharine Peterson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Katharine Peterson | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 31,900 | 31,900 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 116 | 4,419 | - | 5.4 | 629 | Common Stock |
| Acrivon Therapeutics Inc | Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 99 | 4,535 | - | 7.9 | 784 | Common Stock |
| Acrivon Therapeutics Inc | Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 99 | 4,634 | - | 7.0 | 695 | Common Stock |
| Acrivon Therapeutics Inc | Katharine Peterson | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 99 | 4,733 | - | 8.4 | 828 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges